Source comparison
BPC-157 Studied Leaky Gut: Comparison of Routes & Dosing Strategies
Intraperitoneal Injection 10–100 mcg/kg Indirect. Systemic circulation first Low. Not viable in humans Standard in research but no clinical equivalent Subcutaneous Injection 10–50 mcg/kg Systemic, then localized via angiogenesis Moderate. Used in wound healing
This comparison does not assign a generated winner or score.
- Intraperitoneal Injection
- 10–100 mcg/kg
- Indirect. Systemic circulation first
- Low. Not viable in humans
- Standard in research but no clinical equivalent
- Subcutaneous Injection
- 10–50 mcg/kg
- Systemic, then localized via angiogenesis
- Moderate. Used in wound healing trials
- Most predictable for controlled dosing
- Oral Gavage
- Direct mucosal contact, survives gastric acid
- High. Feasible for human oral administration
- Practical route if peptide stability holds in human GI tract
- Rectal Administration
- 10 mcg/kg
- Direct colonic mucosa contact
- Moderate. Used in IBD experimental models
- Targeted delivery to distal colon in colitis models